Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal vs Intramuscular Nalmefene in Healthy Volunteers
NCT04759768Phase 1Completed
- Sponsor
- Opiant Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nalmefene in opioid overdose (2 arms), sponsored by Opiant Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Maximum Plasma Concentration at 48 hours and 2 more. Started Feb 2021; status: completed.
02
Drugs
nalmefene
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT04759768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759768.